Petros Fessas1, Paolo Spina2, Renzo L Boldorini3, Mario Pirisi4, Rosalba Minisini4, Francesco A Mauri1, Fraser Simpson5, Paola Olivieri5, Alessandra Gennari4, Ching Ngar Wong1, Abdul Siddique1, Robert D Goldin6, Ayse U Akarca7, Teresa Marafioti7, David J Pinato1,4,8. 1. Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120 HS, UK. 2. Cantonal Institute of Pathology, Via in Selva 24, 6601 Locarno, Switzerland. 3. Department of Health Sciences, Universitá degli Studi del Piemonte Orientale "A. Avogadro", Via Solaroli 17, 13100 Novara, Italy. 4. Department of Translational Medicine, Università degli Studi del Piemonte Orientale, 13100 Novara, Italy. 5. Department of Genetics, Evolution and Environment & Cell and Developmental Biology, University College London, London WC1E 6BT, UK. 6. Centre for Pathology, Imperial College London, London SW7 2AZ, UK. 7. Department of Histopathology, University College London Hospital, London SW7 2AZ, UK. 8. Clinical Senior Lecturer and Consultant in Medical Oncology, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0HS, UK.
Abstract
(1) Background: The intra-tumoural heterogeneity (ITH) of hepatocellular carcinoma (HCC) and its microenvironment (TME) across primary and secondary disease is poorly characterised. (2) Methods: Intra-tumoural (IT) and peri-tumoural (PT) staining of matched primary and secondary samples was conducted to evaluate the distribution of CD4+/FOXP3+ and CD8+/PD1+ T-cells. Samples underwent PD-L1/2 immunostaining, tumour mutational burden (TMB) evaluation, and high-resolution T-cell receptor (TCR) sequencing to derive T-cell clonality and targeted transcriptomics. (3) Results: We analysed 24 samples from matched primary (n = 11) and secondary (n = 13; 5 synchronous, 6 metachronous) deposits, 11 being extrahepatic (84.6%). IT CD8+ density was lower than PT in both primary (p = 0.005) and secondary deposits (p = 0.01), consistent with immune exclusion. PD-L1+ tumours displayed higher IT and PT CD8+/PD1+ cell density compared to PD-L1- (p < 0.05), and primary IT infiltrate was enriched in CD4+/FOXP3+ cells, compared to PT regions (p = 0.004). TCR-sequencing demonstrated enrichment of the top T-cell clonotype in secondary versus primary HCC (p = 0.02), without differences in overall productive clonality (p = 0.35). TMB was similar across primary versus secondary HCC (p = 0.95). While directed gene set analysis demonstrated the uniformity of transcriptional signatures of individual immune cell types, secondary deposits demonstrated higher COLEC12 (p = 0.004), CCL26 (p = 0.02), CD1E (p = 0.02) and CD36 (p = 0.03) expression with downregulation of CXCL1 (p = 0.03), suggesting differential regulation of innate immunity. (4) Conclusion: Immune exclusion is a defining feature of the HCC TME. Despite evidence of homogeneity in somatic TMB, secondary HCC is characterised by the expansion of a distinct T-cell clonotype and differential regulation of innate immune pathways.
(1) Background: The intra-tumoural heterogeneity (ITH) of hepatocellular carcinoma (HCC) and its microenvironment (TME) across primary and secondary disease is poorly characterised. (2) Methods:Intra-tumoural (IT) and peri-tumoural (PT) staining of matched primary and secondary samples was conducted to evaluate the distribution of CD4+/FOXP3+ and CD8+/PD1+ T-cells. Samples underwent PD-L1/2 immunostaining, tumour mutational burden (TMB) evaluation, and high-resolution T-cell receptor (TCR) sequencing to derive T-cell clonality and targeted transcriptomics. (3) Results: We analysed 24 samples from matched primary (n = 11) and secondary (n = 13; 5 synchronous, 6 metachronous) deposits, 11 being extrahepatic (84.6%). IT CD8+ density was lower than PT in both primary (p = 0.005) and secondary deposits (p = 0.01), consistent with immune exclusion. PD-L1+ tumours displayed higher IT and PT CD8+/PD1+ cell density compared to PD-L1- (p < 0.05), and primary IT infiltrate was enriched in CD4+/FOXP3+ cells, compared to PT regions (p = 0.004). TCR-sequencing demonstrated enrichment of the top T-cell clonotype in secondary versus primary HCC (p = 0.02), without differences in overall productive clonality (p = 0.35). TMB was similar across primary versus secondary HCC (p = 0.95). While directed gene set analysis demonstrated the uniformity of transcriptional signatures of individual immune cell types, secondary deposits demonstrated higher COLEC12 (p = 0.004), CCL26 (p = 0.02), CD1E (p = 0.02) and CD36 (p = 0.03) expression with downregulation of CXCL1 (p = 0.03), suggesting differential regulation of innate immunity. (4) Conclusion: Immune exclusion is a defining feature of the HCC TME. Despite evidence of homogeneity in somatic TMB, secondary HCC is characterised by the expansion of a distinct T-cell clonotype and differential regulation of innate immune pathways.
Authors: Alexandre Reuben; Rachel Gittelman; Jianjun Gao; Jiexin Zhang; Erik C Yusko; Chang-Jiun Wu; Ryan Emerson; Jianhua Zhang; Christopher Tipton; Jun Li; Kelly Quek; Vancheswaran Gopalakrishnan; Runzhe Chen; Luis M Vence; Tina Cascone; Marissa Vignali; Junya Fujimoto; Jaime Rodriguez-Canales; Edwin R Parra; Latasha D Little; Curtis Gumbs; Marie-Andrée Forget; Lorenzo Federico; Cara Haymaker; Carmen Behrens; Sharon Benzeno; Chantale Bernatchez; Boris Sepesi; Don L Gibbons; Jennifer A Wargo; William N William; Stephen Swisher; John V Heymach; Harlan Robins; J Jack Lee; Padmanee Sharma; James P Allison; P Andrew Futreal; Ignacio I Wistuba; Jianjun Zhang Journal: Cancer Discov Date: 2017-07-21 Impact factor: 39.397
Authors: Ivo Buchhalter; Eugen Rempel; Volker Endris; Michael Allgäuer; Olaf Neumann; Anna-Lena Volckmar; Martina Kirchner; Jonas Leichsenring; Amelie Lier; Moritz von Winterfeld; Roland Penzel; Petros Christopoulos; Michael Thomas; Stefan Fröhling; Peter Schirmacher; Jan Budczies; Albrecht Stenzinger Journal: Int J Cancer Date: 2018-12-04 Impact factor: 7.396
Authors: David J Pinato; Anu Vallipuram; Joanne S Evans; Clement Wong; Hua Zhang; Matthew Brown; Roberto E Dina; Pritesh Trivedi; Ayse U Akarca; Teresa Marafioti; Francesco A Mauri; Rohini Sharma Journal: Neuroendocrinology Date: 2020-02-25 Impact factor: 4.914
Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Alexander R Abbas; Marina Ruiz de Galarreta; Yinghui Guan; Andrew X Zhu; Shan Lu; Hartmut Koeppen; Wenjun Zhang; Chih-Hung Hsu; Aiwu Ruth He; Baek-Yeol Ryoo; Thomas Yau; Ahmed O Kaseb; Adam M Burgoyne; Farshid Dayyani; Jessica Spahn; Wendy Verret; Richard S Finn; Han Chong Toh; Amaia Lujambio; Yulei Wang Journal: Nat Med Date: 2022-06-23 Impact factor: 87.241